American Academy of Ophthalmology

At AAO 2024, Quan Dong Nguyen, MD, and Jia-Horung Hung, MD, discuss the Phase 2 Neptune trial investigating brepocitinib for active non-infectious uveitis.

At AAO 2024, Wykoff discussed first-time extended results from AMARONE showing Restoret’s effectiveness in improving outcomes for patients with DME and nAMD.

At AAO 2024, Kay presented an overview of gildeuretinol, an oral vitamin A derivative offering hope for patients with Stargardt disease.

At AAO 2024, Khurana discussed rapid visual and structural gains for uveitic macular edema with vamikibart, paving the way for Phase 3 trials.

At AAO 2024, Garg describes an analysis of the Phase 2/3 PHOTON trial evaluating the effect of DME treatment history on aflibercept 8 mg and 2 mg outcomes.

At AAO 2024, HO described meaningful BCVA improvements in patients with retinitis pigmentosa observed through 2 years of the Phase 2b/3 RESTORE trial.

At AAO 2024, Kay describes encouraging interim safety and efficacy results from the ATSN-201 gene therapy trial in patients with X-linked retinoschisis.

At AAO 2024, Khanani discussed data showing a 97% reduction in annualized injection needs at 9 months with RGX-314 gene therapy.

Decreasing Vitamin A dimerization could be a potential mechanism to treat geographic atrophy, according to results from the two-year SAGA study at AAO 2024.

Pegcetacoplan injection showed increased benefit for subfoveal GA, with as few as 6 injections, over 3 years in the GALE extension trial.

At AAO 2024, Pearlman discusses how an innovative oral approach may provide an alternative pathway to existing treatments for DME.

At AAO 2024, Goldberg described pooled visual function data from 3 randomized, controlled clinical trials evaluating NT-501 for patients with MacTel.

At AAO 2024, Borkar discusses the visual acuity benefit of ONL1204 ophthalmic solution for patients with macula-off rhegmatogenous retinal detachment.

TRS01 eye drops demonstrate a positive benefit-risk profile for potential use as a first-line treatment in anterior non-infectious uveitis.

At AAO 2024, Do describes the durable vision gains and anatomic improvements achieved with aflibercept 8 mg for DME over 3 years of the PHOTON trial.

In the Phase 2 ARCHER trial, ANX007 protected against visual acuity loss and remained well-tolerated for patients with geographic atrophy.

At AAO 2024, Schneider explains the pivotal trial outcomes of AI-based home OCT, compared with standard in-office OCT scans.

At AAO 2024, Cunningham describes the clinical response and safety of faricimab (Vabysmo) in underrepresented populations with diabetic macular edema.

A history of anti-VEGF injections for retinal conditions may increase the incidence of complications after cataract surgery.

OCU400 gene therapy remained safe and tolerable across different mutation and dose cohorts in retinitis pigmentosa and Leber congenital amaurosis.

Real-world data from the FARETINA-AMD study show faricimab extended treatment intervals among eyes with nAMD.

Most ophthalmology teaching faculty noted their lack of awareness about available resources or training as a barrier, rather than a lack of time, perceived benefit, or funding.

At AAO 2023, Korobelnik provides insight into the efficacy and safety of aflibercept 8 mg in patients with nAMD observed over 2 years of the PULSAR study.

At AAO 2023, Kay shares insight into the topline results of the TEASE-1 study investigating the effect of gildeuretinol (ALK-001) on the inherited retinal disease.

At AAO 2023, David Lally, MD describes results from the phase 2 ARCHER study and the potential benefit of intravitreal ANX007 for patients with GA.

Presented at AAO 2023, Kendra Klein-Mascia, MD, discussed her team’s study, comparing faricimab with aflibercept. The study found 2 injections of faricimab gets rid of 75% of retina fluid by week 8, but for aflibercept, erasing the same amount of fluid takes 3 injections until week 12.

Phase 3 results from the GATHER2 trial show the treatment effect of avacincaptad pegol for geographic atrophy more than doubled over 2 years compared to year 1 of study.

Presented at AAO 2023, a study analyzed which race was associated more with having a glaucoma-associated diagnosis, as well as races’ knowledge, attitude, and beliefs about eye care.

Eligibility criteria prevents more Black individuals than White individuals from participating in clinical trials for diabetic macular edema.

Presented at AAO 2023, new data show dual Ang-2/VEGF-A inhibition with faricimab improved pigment epithelial detachment outcomes versus aflibercept.